Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BrainsWay Ltd. (BWAY.TA)
Jerusalem, IL
Established in Jerusalem, Israel, in 2003, BrainsWay Ltd. specializes globally in creating and distributing advanced, non-invasive neurostimulation therapies designed to address a wide array of mental health and neurological conditions. The company's primary innovation is its Deep Transcranial Magnetic Stimulation (dTMS) platform, which offers treatment for disorders including major and anxious depression, obsessive-compulsive disorder, nicotine addiction, bipolar disorder, post-traumatic stress disorder, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's solutions are primarily adopted by psychiatric practitioners, hospitals, and medical centers across the United States, Europe, Israel, and other international markets.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.02% | -11.30% | +14.51% | +79.10% | +40.93% | +129.97% | +1,422.30% | +158.91% | +174.73% | +238.04% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+37.8% ★ Q1'26: +34.6% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+111.1% ★ Q1'26: +200.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+18.4% ★ Q1'26: +2.6% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+8.3% ★ Q1'26: +17.6% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+42.4% ★ Q1'26: +45.6% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+22.0% Q1'26: +3.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.07× ★ Q1'26: 0.52× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. |
Dec 2027 3 Rev. Ana. |
|---|---|---|---|---|---|
| Revenue |
31.79M
est: 31.55M (+0.8%)
|
41.02M
est: 11.11M (+269.3%)
|
56.53M
est: 16.22M (+248.6%)
|
21.30M
20.85M – 21.68M
+31.3% YoY
|
26.11M
24.94M – 27.45M
+22.6% YoY
|
| EBITDA |
-2.56M
est: -4.33M (+40.8%)
|
5.36M
est: -925.7K (+678.7%)
|
6.34M
est: -1.35M (+569.4%)
|
-1.78M
-1.81M – -1.74M
-31.3% YoY
|
-2.18M
-2.29M – -2.08M
-22.6% YoY
|
| EBIT |
-3.90M
est: -6.04M (+35.5%)
|
3.59M
est: -1.43M (+350.4%)
|
4.68M
est: -2.09M (+323.8%)
|
-2.75M
-2.80M – -2.69M
-31.3% YoY
|
-3.37M
-3.54M – -3.22M
-22.6% YoY
|
| Net Income |
-4.20M
est: -5.10M (+17.8%)
|
2.92M
est: 1.28M (+127.9%)
|
8.26M
est: 6.45M (+28.0%)
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
21.64M
est: 22.53M (-4.0%)
|
21.03M
est: 7.40M (+184.1%)
|
27.56M
est: 10.81M (+154.9%)
|
14.20M
13.90M – 14.45M
+31.3% YoY
|
17.41M
16.63M – 18.30M
+22.6% YoY
|
| EPS |
-0.13
est: -0.15 (+11.4%)
|
0.09
est: 0.03 (+184.9%)
|
0.22
est: 0.15 (+43.1%)
|
—
— – —
-100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.07% | 767.5K | 0.40% |
| 2 | iShares Ageing Population UCITS ETF AGED.L | 0.05% | 466.9K | 0.40% |
| 3 | iShares International Small-Cap Equity Factor ETF ISCF | 0.02% | 128.6K | 0.24% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hadar Levy | Chief Executive Officer | 542.5K | male |
| Michael Cohen | Vice President of US Sales | 397.4K | male |
| Colleen Hanlon | Vice President of Medical Affairs | 327.5K | — |
| Ido Marom | Chief Financial Officer | 303.2K | male |
| Yiftach Roth | Founder & Chief Scientific Officer | 108.0K | — |
| Abraham Zangen | Co-Founder, Member of Scientific Advisory Board & Director | 69.9K | — |
| Avner Hagai | Founder & Director | 42.0K | male |
| David Zacut | Co-Founder & Vice-Chairman | 40.2K | — |
| Gilead Moiseyev | Chief Technology Officer | — | male |
| Dor Hagai | Vice President of Operations | — | male |
| Menachem C. Klein | Vice President, General Counsel & Corporate Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BWAY.TA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
